DE60034428D1 - Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker - Google Patents

Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker

Info

Publication number
DE60034428D1
DE60034428D1 DE60034428T DE60034428T DE60034428D1 DE 60034428 D1 DE60034428 D1 DE 60034428D1 DE 60034428 T DE60034428 T DE 60034428T DE 60034428 T DE60034428 T DE 60034428T DE 60034428 D1 DE60034428 D1 DE 60034428D1
Authority
DE
Germany
Prior art keywords
recipient
transplant
administering
combination
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60034428T
Other languages
English (en)
Other versions
DE60034428T2 (de
Inventor
Stuart J Knechtle
Allan D Kirk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Application granted granted Critical
Publication of DE60034428D1 publication Critical patent/DE60034428D1/de
Publication of DE60034428T2 publication Critical patent/DE60034428T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60034428T 1999-01-08 2000-01-06 Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker Expired - Fee Related DE60034428T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11525299P 1999-01-08 1999-01-08
US115252P 1999-01-08
PCT/US2000/000284 WO2000040270A2 (en) 1999-01-08 2000-01-06 Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28

Publications (2)

Publication Number Publication Date
DE60034428D1 true DE60034428D1 (de) 2007-05-31
DE60034428T2 DE60034428T2 (de) 2008-01-03

Family

ID=22360179

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60034428T Expired - Fee Related DE60034428T2 (de) 1999-01-08 2000-01-06 Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker

Country Status (9)

Country Link
EP (1) EP1144010B1 (de)
AT (1) ATE359826T1 (de)
AU (1) AU768547B2 (de)
CA (1) CA2358435A1 (de)
DE (1) DE60034428T2 (de)
DK (1) DK1144010T3 (de)
ES (1) ES2286006T3 (de)
PT (1) PT1144010E (de)
WO (1) WO2000040270A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US7517527B2 (en) 1995-10-30 2009-04-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin with in vivo T cell suppressant activity and methods of use
AU733898B2 (en) 1997-03-05 2001-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxins and methods of inducing immune tolerance
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2191733A1 (en) * 1994-06-07 1995-12-21 Daniel A. Vallera Methods for inhibiting antigen specific t cell responses
CA2218166C (en) * 1995-04-14 2012-08-14 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of inducing immune tolerance using immunotoxins
AU733898B2 (en) * 1997-03-05 2001-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunotoxins and methods of inducing immune tolerance
BR9809641A (pt) * 1997-05-17 2000-07-11 Biogen Inc Uso de um interruptor de ligação cd40:cd154 para evitar respostas imunes inadaptadas, particularmente rejeição a enxerto
WO1998056417A1 (en) * 1997-06-11 1998-12-17 The United States Of America, Represented By The Secretary Of The U.S. Department Of The Navy Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
EP1073463B1 (de) * 1998-04-22 2009-07-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verwendung von immunotoxinen zur auslösung einer immuntoleranz bei transplantation der inselzellen der bauchspeicheldrüse

Also Published As

Publication number Publication date
AU2601700A (en) 2000-07-24
WO2000040270A2 (en) 2000-07-13
EP1144010B1 (de) 2007-04-18
CA2358435A1 (en) 2000-07-13
DE60034428T2 (de) 2008-01-03
WO2000040270A3 (en) 2001-10-18
PT1144010E (pt) 2007-07-20
ES2286006T3 (es) 2007-12-01
AU768547B2 (en) 2003-12-18
ATE359826T1 (de) 2007-05-15
EP1144010A2 (de) 2001-10-17
EP1144010A3 (de) 2002-02-06
DK1144010T3 (da) 2007-09-03

Similar Documents

Publication Publication Date Title
ATE163191T1 (de) Silberkorrosionsschutzmittel i
HK1026654A1 (en) Four-way diesel exhaust catalyst and method of use
DE69705947D1 (de) Zusammensetzungen für körperreinigungsmittel in stückform, mit riechstoff freigebendem komplex
AU3490300A (en) Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
NO976031L (no) Lavviskös, höykonsentrert friksjonsreduserende middel og fremstilling derav
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
ATE162945T1 (de) Mittel zur transdermalen applikation enthaltend 3-keto-desogestrel
DE69627343D1 (de) Dieselmotorabgaskatalysator und verwendungsmethode
TR199801348T2 (xx) Heterosikl-kondanse morfinoid t�revleri(II).
ATE359823T1 (de) Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
FR2709953B1 (fr) Composition cosmétique contenant au moins un agent tensio-actif non-ionique du type alkylpolyglycoside et/ou polyglycérolé et au moins un copolymère séquencé polydiméthylsiloxane/polyoxalkylène.
DE60034428D1 (de) Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker
ZA991170B (en) Mufflers for use with engine retarders; and methods.
FR2649622B1 (fr) Composition catalytique a base de zeolithe y, utilisable dans le traitement d'effluents oxygenes contenant des nox, sa preparation et son application
FR2662159B1 (fr) Nouveaux ligands thio-ethers et leur utilisation pour separer le palladium de solutions aqueuses, en particulier de soludtions nitriques de dissolution d'elements combustibles nucleaires irradies.
TR200003622T2 (tr) Zayıflatılımış Pestivirüsler.
DK0649427T3 (da) Sekventiel fjernelse af monosaccharider fra den reducerende ende af oligosaccharider og anvendelser deraf
ES2191625T3 (es) Composicion oral que contiene perlita.
ES2154018T3 (es) Soluciones inyectables por via parenteral que contienen piroxicam.
ATE200847T1 (de) Zusammensetzung und deren verwendung
FR2784381B1 (fr) Compose fongicide, composition le contenant et son utilisation
DE69200739D1 (de) Carbostyrilderivate und diese enthaltende pharmazeutische Zusammensetzungen zur Verwendung als Mittel zur Verbesserung der Störung des Bewusstseinszustandes, ZNS-Stimulans oder Sigma-Rezeptor-Agonist.
BR9914722A (pt) Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool
FR2818134B1 (fr) Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent antimicrobien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee